Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review updated data from trial evaluating CD47-blocker evorpacept in HER2-positive gastric cancer SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 ...
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies ...
ALX, a prominent tech career accelerator dedicated to nurturing young talent across Africa, held a Parents Forum in Lagos to unveil its innovative ALX Pathway Programme. This new initiative aims to ...
ALX Oncology (ALXO) will host a virtual event on Tuesday, December 17, at 5:00 AM PST / 8:00 AM EST to discuss the first data from a Phase 1b/2 clinical trial evaluating the company’s investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback